EU MDR Transition Deadlines 2026-2028: Critical Dates Every Manufacturer Must Know

The transition from the Medical Devices Directive (MDD 93/42/EEC) and the Active Implantable Medical Devices Directive (AIMDD 90/385/EEC) to the Medical Device Regulation (EU) 2017/745 (MDR) represents the most consequential regulatory transformation the European medical device industry has experienced in three decades. The MDR entered into force on 25 May 2017 and became fully applicable on 26 May 2021, replacing a directive-based framework with a directly applicable regulation that eliminated the latitude member states previously enjoyed in national transposition. The regulation introduced substantially elevated requirements across every dimension of the product lifecycle: classification rules were expanded from 18 to 22, with several product categories reclassified into higher risk classes; technical documentation requirements under Annex II and Annex III became significantly more prescriptive; clinical evaluation expectations shifted decisively toward demonstrating clinical benefit through robust clinical evidence rather than relying primarily on equivalence claims; post-market surveillance obligations were transformed from a largely passive exercise into a proactive, systematic, and data-driven discipline; and the Unique Device Identification (UDI) system mandated traceability throughout the supply chain. The original transition period was designed to conclude on 26 May 2024, by which date all devices on the EU market were expected to hold MDR certificates. However, it became evident by 2022 that the combination of limited Notified Body capacity, the sheer volume of legacy devices requiring recertification, and the elevated documentation standards meant that the original timeline was unachievable without risking widespread device shortages. The European Commission, recognizing this systemic risk to patient access, intervened with legislative amendments that extended the transition deadlines while imposing strict conditions to ensure that safety and performance standards were maintained throughout the extended period.

Regulation (EU) 2023/607 of the European Parliament and of the Council, adopted on 15 March 2023, amended the MDR to extend the transition periods for legacy devices and to introduce additional provisions aimed at preventing critical device shortages. This amendment was the culmination of extensive stakeholder consultation and reflected a pragmatic acknowledgment that the original transition timeline, while well-intentioned, had collided with structural capacity constraints that no amount of manufacturer diligence could overcome. The amendment introduced a tiered deadline structure based on device risk classification, replacing the previous single cut-off date. It also removed the so-called "sell-off date" that would have prohibited the making available of already-placed devices after 26 May 2025, thereby providing supply chain continuity. Critically, the extended deadlines are not unconditional. The regulation specifies that manufacturers may only benefit from the extended transition if they meet all of the following conditions simultaneously: the device must have a valid MDD or AIMDD certificate that was issued before 26 May 2021 (or a valid declaration of conformity drawn up before that date for devices that did not require Notified Body involvement under the legacy directives); the manufacturer must have submitted a formal application to a Notified Body for MDR conformity assessment before the relevant deadline; a written agreement with the Notified Body must be in place; the device must continue to comply with the applicable legacy directive; there must be no significant changes in the design or intended purpose that would require a new conformity assessment; and the manufacturer must maintain a quality management system and post-market surveillance system that comply with the MDR requirements set out in Articles 10(10), 10(11), 10(12), 10(14), and the relevant provisions of Articles 83 through 86. Manufacturers who fail to meet any one of these conditions lose their entitlement to the extended transition and must withdraw the affected devices from the market.

The first critical deadline under the amended transition framework falls on 31 December 2027 and applies to all Class III devices and Class IIb implantable devices. These represent the highest-risk categories in the MDR classification system and include products such as hip and knee implants, cardiac pacemakers, drug-eluting stents, breast implants, total artificial hearts, cochlear implants, implantable neurostimulators, and any Class IIb device that is intended to be totally or partially introduced into the human body. After 31 December 2027, no device in these classes may be placed on the EU market under a legacy MDD or AIMDD certificate, regardless of the certificate expiry date. This deadline is now less than 22 months away, and manufacturers who have not yet secured a written agreement with a Notified Body are in an extremely precarious position. The conformity assessment process for Class III devices under the MDR is substantially more intensive than under the MDD. It includes a full audit of the quality management system, a thorough review of the complete technical documentation including clinical evaluation, scrutiny of the post-market clinical follow-up plan, and for certain device types, a clinical evaluation consultation procedure involving an expert panel. For implantable Class IIb devices, the requirements are similarly demanding, particularly with respect to clinical evidence and biocompatibility data. Manufacturers should be aware that Notified Bodies are reporting typical assessment timelines of 12 to 18 months from the point of documentation submission to certificate issuance, assuming the documentation is complete and of sufficient quality. When documentation deficiencies are identified, which occurs in a significant majority of initial submissions, the timeline extends further as manufacturers must respond to observations, revise documentation, and potentially undergo additional audits. The practical implication is stark: any manufacturer of a Class III or implantable Class IIb device that does not have an active, progressing MDR application by mid-2026 faces a material risk of missing the 31 December 2027 deadline.

The second tier of the extended transition concludes on 31 December 2028 and covers Class IIa devices, Class IIb non-implantable devices, and Class I devices that are placed on the market in a sterile condition or that have a measuring function. This broader category encompasses a vast range of products, including surgical instruments supplied sterile, diagnostic equipment with measuring functions, powered surgical tools, patient monitoring accessories, infusion and transfusion devices, wound care products classified as Class IIa, dental devices, ophthalmic devices, and many other categories. While these devices generally present a lower risk profile than Class III implantables, the MDR conformity assessment requirements remain substantially more demanding than under the legacy directives. For Class IIa devices, the MDR requires Notified Body involvement through either an Annex IX quality management system audit or an Annex XI product-level type examination, combined with ongoing surveillance. Class IIb non-implantable devices face the most intensive Annex IX pathway with technical documentation assessment. Class I sterile and measuring devices, which under the MDD required Notified Body involvement only for the sterile or measuring aspects, now face a more comprehensive assessment scope. The additional year provided to this tier, compared to the Class III and IIb implantable deadline, reflects both the lower risk profile and the recognition that Notified Body resources freed up after the 2027 deadline for higher-risk devices can be redirected to this category. However, manufacturers should not interpret this additional year as an invitation to delay. Given the volume of devices in these classes and the continuing constraints on Notified Body capacity, early engagement remains essential. Manufacturers of Class IIa devices in particular should note that while the individual assessment for each product type may be less intensive than for Class III, many manufacturers hold portfolios of dozens or hundreds of Class IIa products, and the aggregate documentation effort is substantial.

The conditions attached to the extended transition deadlines deserve careful and detailed examination, as failure to satisfy any single condition results in the loss of the right to place the device on the market. The first condition requires a valid MDD or AIMDD certificate issued before 26 May 2021. Manufacturers must verify that their certificates have not been withdrawn, suspended, or allowed to lapse. For devices that were self-declared under the MDD (certain Class I devices with sterile or measuring function where Notified Body involvement was limited to those specific aspects), the relevant condition is that a valid declaration of conformity was drawn up before 26 May 2021. The second condition, the requirement to have submitted an application to a Notified Body, is where many manufacturers encounter practical difficulties. A credible application means a formal submission of the MDR technical documentation, not merely an expression of interest or a preliminary inquiry. Notified Bodies are increasingly scrutinizing whether applications are substantive and complete enough to constitute a genuine submission. The third condition, the written agreement with a Notified Body, must document the scope of the conformity assessment, the device or device group covered, the applicable conformity assessment procedure, and a reasonable timeline for completion. The MDCG has provided guidance on what constitutes an acceptable written agreement, and manufacturers should ensure their agreements meet these expectations. The fourth condition relates to continued compliance with the legacy directive. This means that the quality management system certified under the MDD must remain operational and subject to ongoing surveillance by the MDD Notified Body. Manufacturers cannot simply abandon their MDD obligations while awaiting MDR certification. The fifth condition requires that the manufacturer has implemented the MDR post-market surveillance, market surveillance, and vigilance requirements. This means that even before obtaining an MDR certificate, manufacturers must operate their PMS and vigilance systems in accordance with MDR Articles 83 to 86 and the associated implementing acts. This is a substantive obligation that requires investment in PMS infrastructure, PSUR generation, trend reporting, and vigilance reporting through the MDR-specified channels.

The European Database on Medical Devices (EUDAMED) represents a cornerstone of the MDR transparency and traceability framework, and its phased deployment continues to create compliance obligations that run in parallel to the transition deadlines. The Actor Registration module has been operational and mandatory since 2021. All economic operators, including manufacturers, authorised representatives, importers, and system and procedure pack producers, must be registered in EUDAMED with a valid Single Registration Number (SRN). This is a prerequisite for all subsequent EUDAMED interactions. The UDI/Device Registration module is scheduled to become fully mandatory from May 2026, at which point manufacturers must register all devices placed on the EU market and assign UDI-DIs from an accredited issuing entity (GS1, HIBCC, ICCBBA, or IFA). For devices already on the market under the transition provisions, manufacturers should begin populating the UDI database proactively rather than waiting for the mandatory date, as the data entry process for large device portfolios is time-consuming and error-prone if rushed. The remaining EUDAMED modules, covering Notified Body and certificate data, clinical investigations, vigilance reporting, and market surveillance, are in various stages of development and testing. The European Commission has indicated that these modules will become mandatory in a staggered sequence, with the certificates and Notified Body module expected next, followed by clinical investigations and vigilance. Manufacturers should monitor the Commission communications and MDCG guidance for specific mandatory dates as they are confirmed. It is worth noting that EUDAMED functionality, while improving, has been subject to delays and technical challenges since the inception of the project. Manufacturers should allocate sufficient resources for EUDAMED data management, including designating responsible personnel, establishing data quality processes, and ensuring that UDI data is consistent with the technical documentation and device labelling. Discrepancies between EUDAMED data and other regulatory submissions are an increasingly common finding during Notified Body audits and competent authority inspections.

Switzerland, as a non-EU member state, maintains its own regulatory framework for medical devices, though it has historically been closely aligned with the EU system through the Mutual Recognition Agreement (MRA). The Swiss Medical Devices Ordinance (MedDO), which took effect on 26 May 2021, incorporates the substance of the EU MDR into Swiss law, including the extended transition provisions mirroring Regulation (EU) 2023/607. However, the MRA between Switzerland and the EU on conformity assessment for medical devices has not been updated to reflect the MDR, meaning that Swiss and EU market access are no longer automatically reciprocal. Manufacturers holding Swiss certificates cannot assume automatic EU market acceptance, and vice versa. This situation creates additional regulatory complexity, particularly for manufacturers who serve both markets. Swissmedic, the Swiss Agency for Therapeutic Products, has been developing Swissdamed, the Swiss equivalent of EUDAMED. Swissdamed is intended to provide the registration, UDI, and vigilance database functions required under the MedDO. Swiss UDI requirements are being implemented on a timeline that largely parallels the EU schedule but with Swiss-specific implementation details. Manufacturers placing devices on the Swiss market must register with Swissmedic and ensure compliance with MedDO-specific requirements, which in some areas diverge slightly from the EU MDR. For manufacturers based in Switzerland who also serve the EU market, the practical implication is that they must maintain compliance with both the MedDO and the EU MDR, potentially requiring separate conformity assessment processes, separate Authorised Representative appointments for the EU market, and parallel regulatory submissions. Swiss MPC, headquartered in Cham, Switzerland, has deep expertise in navigating both frameworks and advising manufacturers on efficient strategies for dual-market compliance. It is essential that manufacturers do not assume that Swiss MedDO compliance automatically translates to EU MDR compliance, or that an EU MDR certificate provides unrestricted Swiss market access without additional Swissmedic registration and compliance verification.

Notified Body capacity remains the single most significant structural constraint affecting the MDR transition, and manufacturers who underestimate its implications do so at considerable commercial risk. As of early 2026, approximately 40 Notified Bodies have been designated under the MDR, compared to over 80 that operated under the MDD. This consolidation reflects the substantially more rigorous designation requirements under the MDR, which include enhanced competency requirements for auditors, more intensive oversight by national designating authorities, and regular joint assessments. While 40 designated bodies may appear adequate in absolute terms, the reality is that each body has finite capacity in terms of qualified auditors, technical reviewers, and administrative infrastructure. The aggregate capacity of the MDR Notified Body system is not yet sufficient to process the full volume of legacy devices requiring transition alongside new MDR applications. Manufacturers report wait times of 6 to 12 months from initial inquiry to formal application acceptance, followed by an additional 12 to 18 months for the conformity assessment process itself. For complex Class III devices, the total timeline from initial engagement to certificate issuance frequently exceeds 24 months. These timelines assume well-prepared technical documentation. When significant deficiencies are identified during the review, manufacturers may face multiple rounds of questions, additional audits, and documentation revision cycles that can add 6 to 12 months to the process. The competitive dynamics around Notified Body capacity have created a sellers market in which Notified Bodies can be selective about the applications they accept. Bodies increasingly prioritize manufacturers with mature quality management systems, well-structured technical documentation, and demonstrated readiness for MDR compliance. Manufacturers who approach a Notified Body with incomplete documentation, unresolved classification questions, or inadequate clinical evidence may find their applications deprioritized or declined. The practical lesson is clear: the quality and completeness of your initial submission directly affects not only the speed of your assessment but whether a Notified Body is willing to accept your application at all.

The consequences of missing the applicable transition deadline are severe and immediate. Once the relevant deadline has passed, a device that has not obtained an MDR certificate may no longer be placed on the EU market. "Placed on the market" under EU regulatory terminology means the first making available of a device on the Union market, which encompasses the initial supply of each individual device for distribution, consumption, or use. Devices that have already been placed on the market before the deadline and are in the supply chain (in distributor inventories, hospital stores, or at end users) may continue to be made available, which means they can continue to move through the distribution chain. However, no new units may be manufactured and released onto the market without an MDR certificate. For manufacturers, this effectively means a halt to European revenue for the affected device. The commercial implications extend beyond the direct revenue loss. Distributors and hospital procurement departments are already factoring MDR certification status into their purchasing decisions, and devices perceived as having uncertain regulatory futures are being deprioritized in favour of MDR-certified alternatives. Loss of EU market access may also have cascading effects on market access in jurisdictions that reference EU certification, including parts of the Middle East, Africa, and Asia-Pacific. Furthermore, the reputational damage of a market withdrawal can be difficult to reverse, as healthcare procurement processes are long-cycle and regaining a formulary or approved vendor position once lost may take years. Manufacturers should also be aware of the enforcement mechanisms available to competent authorities. Member state authorities have the power to conduct market surveillance, request documentation, audit manufacturers, and order recalls or withdrawals of non-compliant devices. The MDR strengthened these powers compared to the MDD, and competent authorities have signaled their intention to exercise them more actively. Manufacturers who attempt to remain on the market without valid certification face not only forced withdrawal but also potential administrative sanctions, publication of non-compliance findings, and in serious cases, criminal penalties under national implementing legislation.

A structured, stage-appropriate action plan is essential for manufacturers navigating the transition, and the specific priorities depend on where the manufacturer currently stands in the MDR certification process. For manufacturers who have not yet engaged a Notified Body, the immediate priority is triage. Conduct a portfolio-level assessment to determine which devices are commercially viable under the MDR, which should be discontinued, and which require redesign or reclassification. Not every legacy device justifies the investment required for MDR certification, and strategic portfolio rationalization can free resources for the products that matter most. Once the portfolio is rationalized, identify and approach Notified Bodies with capacity in your device categories. Prepare a complete MDR application package before approaching the Notified Body, as bodies increasingly require evidence of readiness before accepting new clients. For manufacturers who have submitted an application and hold a written agreement but are awaiting their assessment, the priority is documentation excellence. Use the waiting period productively by conducting an internal mock audit of your technical documentation against MDR Annex II requirements, engaging independent regulatory experts to review your clinical evaluation report and PMCF plan, and ensuring your post-market surveillance system is generating the data and reports required under the MDR. Address any known gaps proactively rather than waiting for the Notified Body to identify them, as each round of questions and revisions adds months to the timeline. For manufacturers already in active assessment with their Notified Body, the priority is responsiveness and resource allocation. Assign dedicated personnel to manage the Notified Body relationship and respond to observations promptly and comprehensively. Incomplete or delayed responses to Notified Body questions are among the most common causes of certification delays. Ensure that subject matter experts in clinical, quality, and technical functions are available to support the assessment process without competing demands from other projects.

Class I devices occupy a distinct position in the MDR transition framework that is frequently misunderstood. Unlike higher-risk classes that benefit from extended transition deadlines, Class I devices have been fully subject to MDR requirements since 26 May 2021, with no transition period extension. This means that all Class I devices currently on the EU market must already comply with every applicable MDR requirement, including the General Safety and Performance Requirements of Annex I, the technical documentation requirements of Annexes II and III, the UDI requirements, the post-market surveillance obligations, and the registration requirements. Manufacturers of Class I devices self-declare conformity through a Declaration of Conformity without Notified Body involvement, unless the device is placed on the market in a sterile condition, has a measuring function, or is a reusable surgical instrument, in which case limited Notified Body involvement is required for the sterile, measuring, or reprocessing aspects respectively. The absence of Notified Body oversight for standard Class I devices places a greater burden on manufacturers to self-police their compliance. Competent authorities have noted that compliance rates among Class I device manufacturers are uneven, with particular gaps in clinical evaluation (even Class I devices require a clinical evaluation, though the depth and scope may be proportionate to the risk), post-market surveillance reporting, and UDI implementation. Manufacturers of Class I devices should not assume that the lower risk classification equates to minimal regulatory obligations. The MDR applies its core requirements to all device classes, and the classification primarily affects the conformity assessment procedure rather than the substantive safety and performance requirements. A particular area of concern is the reclassification of certain products under the MDR classification rules. Some products that were unregulated or classified as general wellness devices under the MDD are now classified as Class I medical devices under the MDR, and some former Class I devices have been reclassified to Class IIa or higher. Manufacturers must verify their device classification under the current MDR rules, particularly Rule 11 for software, Rule 21 for nanomaterial-containing devices, and Rule 22 for devices composed of substances absorbed by or dispersed in the body.

Custom-made devices, defined under Article 2(3) of the MDR as devices specifically made in accordance with a written prescription of an authorised prescriber for a specific patient, are subject to a distinct set of requirements that have also evolved significantly under the MDR. Unlike series-manufactured devices, custom-made devices do not bear a CE marking and are not subject to the standard conformity assessment procedures involving Notified Body review. However, this does not mean they are exempt from MDR requirements. Manufacturers of custom-made devices must draw up a statement containing the patient identification, the prescriber identification, the specific characteristics of the device, and a declaration that the device conforms to the General Safety and Performance Requirements of Annex I. They must also maintain technical documentation that describes the design, manufacture, and performance of the device, including sufficient detail to enable the competent authority to assess conformity. Under the legacy MDD, custom-made device manufacturers operated with relatively limited regulatory obligations. The MDR has substantially increased these obligations. Custom-made device manufacturers must now implement a quality management system, maintain a post-market surveillance system, fulfil vigilance reporting obligations, and register their devices in EUDAMED (once the relevant modules are mandatory). For Class III custom-made implantable devices, the MDR introduced an entirely new requirement: these devices must now undergo conformity assessment by a Notified Body, specifically covering the quality management system aspects described in Annex IX, Sections 1 and 2. This represents a fundamental change for manufacturers of custom-made Class III implantables, such as patient-specific orthopaedic implants, cranial plates, and certain dental implants, who must now engage a Notified Body and obtain certification. The transition period for this Notified Body requirement for custom-made Class III implantables has been extended in line with the general Class III transition deadline of 31 December 2027, but manufacturers who have not yet initiated this process are at significant risk of non-compliance.

Given the urgency of the transition timeline, manufacturers benefit from a month-by-month priority framework for 2026 that translates the regulatory deadlines into actionable operational milestones. In January through March 2026, the priority is portfolio and gap assessment. Manufacturers should complete a device-by-device inventory of their EU product portfolio, confirming the MDR classification of each device, the status of each MDD/AIMDD certificate, and the current state of MDR-compliant technical documentation. This is also the period to finalize Notified Body selection and formal engagement for any devices not yet in the application pipeline. From April through June 2026, the focus shifts to documentation completion and EUDAMED readiness. With the UDI/Device Registration module becoming mandatory around May 2026, manufacturers must ensure that UDI-DIs have been obtained from an accredited issuing entity, that device registration data is accurate and complete, and that internal processes are in place for ongoing EUDAMED data maintenance. Simultaneously, this quarter should be used to close any remaining gaps in clinical evaluation reports, post-market surveillance plans, and GSPR checklists for devices in the Notified Body assessment pipeline. During July through September 2026, manufacturers should conduct internal readiness audits focused specifically on the MDR requirements that differ most significantly from the MDD: clinical evaluation depth and methodology, PMCF plan adequacy, PMS system maturity, and compliance with the MDR labelling requirements including UDI carriers on device labels and packaging. This is also the period to prepare for anticipated Notified Body audit activities in Q4. For October through December 2026, the priority for manufacturers of Class III and implantable Class IIb devices becomes critical-path management. With the 31 December 2027 deadline now 12 months away, any manufacturer that has not yet received its first Notified Body audit report or that has unresolved major nonconformities must escalate its response efforts. This quarter should also be used to engage backup Notified Body options if the primary assessment is at risk, and to begin contingency planning for devices that may not achieve certification by the deadline, including evaluating whether bridging solutions, device modifications, or market exit strategies are appropriate.

Navigating the MDR transition requires more than regulatory knowledge. It demands experienced judgment about where to allocate finite resources, how to structure documentation for efficient Notified Body assessment, and when to make difficult strategic decisions about product portfolios. Swiss MPC has supported medical device manufacturers through every phase of this transition since the MDR was first published in 2017. Our senior consultants bring direct experience with the conformity assessment process across all device classes and have established working relationships with major Notified Bodies. We provide comprehensive MDR transition support, including gap analysis against Annex II technical documentation requirements, clinical evaluation and PMCF strategy development, post-market surveillance system design and implementation, UDI implementation and EUDAMED registration support, quality management system alignment to both MDR and MedDO requirements, and Notified Body submission preparation with pre-submission review. Our approach is built on a principle that distinguishes us from larger consultancies: every client engagement is overseen by a senior consultant with direct regulatory authority experience, ensuring that the guidance you receive reflects current regulatory expectations rather than theoretical interpretations. We operate from our headquarters in Cham, Switzerland, and our European office in Galway, Ireland, providing coverage across the EU and Swiss regulatory landscapes. For manufacturers who are assessing their MDR transition readiness, we offer a complimentary initial consultation to evaluate your current position and identify the most critical next steps. Contact us at info@swissmpc.com or call +41 44 586 72 67 to discuss your specific situation. The transition deadlines are fixed, the Notified Body capacity is constrained, and the cost of delay compounds with every passing month. The manufacturers who act decisively now will secure their EU market access. Those who wait risk finding themselves without the regulatory pathway they need when they need it most.